{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-26-000060","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2026-08-06T11:08:34+00:00","discovered_at":"2026-08-06T11:10:07.335831+00:00","generated_at":"2026-08-06T11:10:36.352623+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tarsus to acquire Alkeus for $450M upfront; adds Phase 3 Stargardt drug gildeuretinol","bullets":["Upfront consideration: $270M cash + $180M in Tarsus stock ($61.38/share); total ~$450M.","Milestones up to $350M (regulatory approval + first commercial sale) plus low-single-digit royalties.","Gildeuretinol (ALK-001) is a once-daily oral for Stargardt disease; no FDA-approved therapy exists.","Phase 3 NORTHSTAR trial enrolling ~230 patients; topline data expected H2 2029.","Deal approved by both boards; expected to close in 2026, subject to HSR clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-26-000060","json":"https://secwatch.observer/filing/0001819790-26-000060.json","markdown":"https://secwatch.observer/filing/0001819790-26-000060.md","text":"https://secwatch.observer/filing/0001819790-26-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000060/0001819790-26-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000060/tars-20260731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:10:36.352623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}